Item
5.02
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
|
On
March 3, 2020, Microbot Medical Inc. (the “Company”) issued a press release publicly announcing the appointment of
Dr. Eyal Morag, age 55, to the Company’s newly created position of Chief Medical Officer (“CMO”). As CMO, Dr.
Morag will lead the development and execution of the clinical strategy of the Company, including its current development of the
SCS and LIBERTY products as well as its future pipeline. Dr. Morag is a member of the Company’s Scientific Advisory Board
since November 1, 2017.
Dr.
Morag is certified by the American Board of Radiology, and since March 2017 has been the Chairman of Radiology at Assuta Ashdod
Medical Center, Ashdod, Israel. Previously, from July 2014 through March 2017, he was the senior Radiologist at URG Teleradiology
LLC, the largest provider of subspecialty radiology and teleradiology services in New Jersey.
He
is a graduate of Boston University School of Medicine and completed both his Radiology residency and Fellowship in Cardiovascular
& Interventional Radiology at the Beth Israel Deaconess Medical Center & Harvard Medical School. Following his clinical
training, Dr. Morag then joined a private practice in western Massachusetts, where he served as Chief of Radiology at Holyoke
Medical Center for several years. He has also served as the Regional Radiology Director at Mercy Health Partners Hospitals in
Toledo, Ohio, and was a member of the University Radiology Group where he headed the International Investment efforts for the
Ventures division.
Dr.
Morag’s international experience developing and establishing radiology-related businesses includes teleradiology, interventional
Radiology services, and free-standing imaging centers. During his fellowship, Dr. Morag co-founded InTek Technology, a medical
device startup company. Later he founded Global Versa Radiology (“GVR”), an Israeli and U.S. based teleradiology company.
GVR has established imaging centers in Russia and Ukraine and provided teleradiology services in countries outside the U.S. and
Israel. Dr. Morag served as GVR’s Chief Medical Officer and Vice-President. He continues to be involved in several startup
companies ranging from AI to medical devices. Dr. Morag is also a member of the Advisory Board of MEDX Xelerator, a medical device
and digital health incubator.
The
Company entered into an employment agreement (the “Agreement”), as of February 18, 2020, with Dr. Morag, to serve
as the Company’s Chief Medical Officer, commencing June 15, 2020 (the “Commencement Date”) on an indefinite
basis subject to the termination provisions described in the Agreement. Pursuant to the terms of the Agreement, Dr. Morag shall
receive a base salary of NIS 64,000 per month plus Global Overtime (as defined in the Agreement) of NIS 16,000 per month.
Dr.
Morag shall also be entitled to receive a target annual cash bonus, based on certain milestones, of up to a maximum amount of
30% of annual salary.
Dr.
Morag shall be further entitled to a monthly automobile allowance not to exceed NIS 4,800 per month plus expenses and applicable
taxes, and shall be granted options to purchase 25,000 shares of common stock of the Company based on vesting and other terms
set forth in the Agreement.
Pursuant
to the Agreement, the Company shall pay an amount equal to 8.33% of Dr. Morag’s salary to be allocated for severance pay,
6.5% of Dr. Morag’s salary to be allocated for pension savings and 7.5% to be allocated to an educational fund. The Company
may have additional payment obligations for disability insurance as specified in the Agreement.
During
the initial 24 months following the Commencement Date (“Initial Period”), either the Company or Dr. Morag may terminate
the Agreement at its discretion at any time by providing the other party with a three months (or, following the Initial Period,
six months) prior written notice of termination (the “Advance Notice Period”).
The
Company may terminate the Agreement “For Cause” (as defined in the Agreement) at any time by written notice without
the Advance Notice Period.
In
the event that the Company terminates Dr. Morag’s employment during the Initial Period other than For Cause, Dr. Morag shall
be entitled to a one-time payment in an amount equal to his annual salary as of the date of termination of employment multiplied
by the balance time between the end of the Advance Notice Period and until the end of the Initial Period.
The
agreement contains customary non-competition and non-solicit provisions pursuant to which Dr. Morag agrees not to compete and
solicit with the Company. Dr. Morag also agreed to customary terms regarding confidentiality and ownership of intellectual property.
The
Company also entered into an indemnification agreement with Dr. Morag. Pursuant to the indemnification agreement, the Company
has agreed to indemnify and hold harmless Dr. Morag to the fullest extent permitted by the Delaware General Corporation Law. The
indemnification agreement generally covers expenses that Dr. Morag incurs or amounts that Dr. Morag becomes obligated to pay because
of any proceeding to which he is made or threatened to be made a party or participant by reason of his service as a current or
former officer of the Company, provided that he acted in good faith and in a manner he reasonably believed to be in or not opposed
to the best interests of the Company. The indemnification agreement also provides for the advancement of expenses to Dr. Morag
subject to specified conditions. There are certain exceptions to the Company’s obligation to indemnify Dr. Morag, and, with
certain exceptions, with respect to proceedings that he initiates.
A
copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.